- Dexcom EASD Symposium brings together expert panellists from
across Europe to explore the transformational effects of Dexcom CGM
on clinical practice.
- With the most extensive clinical data and evidence, Dexcom is
the most experienced partner in Automatic Insulin Delivery
(AID)1.
- Studies show the potential for Dexcom CGM to support therapy
de-escalation and optimise diabetes management in Type 2
diabetes.5,6,8
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes, will
spotlight the significant benefits of its innovative CGM technology
at an upcoming symposium during the European Association for the
Study of Diabetes (EASD) Conference on Monday, 9th September, 1300
– 1430 CEST. The symposium will feature expert panellists from
endocrinology Prof. Michael Joubert MD PhD, France, primary care,
Prof. Samuel Seidu MD, FRCP (EDIN), FRCGP, UK, Therapeutic
Education, Dr. oec. troph. Astrid Tombek, Germany and psychology
Ass. Prof. Giesje Nef, PhD, Netherlands and will be chaired by Dr.
Javier Ampudia-Blasco MD, PhD, Spain. Specific topics for the
symposium will include the benefits of Dexcom-powered AID systems
and the increasingly widely studied benefits of Dexcom CGM for
those living with Type 2 diabetes.
“I'm looking forward to chairing this panel of colleagues from
across Europe, who will each bring their unique expertise in
treating patients with different types of diabetes,” said Dr.
Ampudia-Blasco, symposium chair. “With this new approach to their
symposium, Dexcom is offering healthcare professionals a more
engaging and practical perspective on the real-world benefits of
Dexcom CGM. By showcasing how CGM can positively impact a wide
range of patients, it is my hope that we will be supporting the
transformation of clinical practice and helping to drive meaningful
change in healthcare.”
Dexcom: The most experienced AID partner1
Dexcom’s CGM technology is the preferred choice for AID among
healthcare professionals2, powering more AID systems than any other
CGM brand1. Supported by the most extensive clinical data and
evidence, patients using Dexcom-powered AID systems experience an
average of 2.6 more hours in range per day*,3-4.
"Our commitment to innovation and excellence in diabetes
management is unmatched, and our partnerships in advancing AID
technology are a testament to that leadership. We’re not only
shaping the future of diabetes care—we’re driving it forward with
relentless passion and purpose,” said Jake Leach, Executive Vice
President and Chief Operating Officer at Dexcom. “At the heart of
our mission is our unwavering commitment to the diabetes community.
Every decision we make is driven by our dedication to improving
their lives and empowering them to manage diabetes with
confidence."
With hundreds of thousands of users now connected to insulin
pumps, pens, and digital health apps, Dexcom is the undisputed
leader in CGM connectivity1.
This year, Dexcom has expanded G7 sensor connectivity, making it
compatible globally with the Tandem t:slim X2 with Control IQ
technology, and in the USA, with Tandem Mobi with Control IQ
technology as well as the Omnipod® 5 Automated Insulin Delivery
System. Dexcom G6 connections with Omnipod® 5 are continuing to
roll out across Europe, most recently in the Netherlands and
France.
Dexcom CGM: Optimising Type 2 Diabetes Management and
Supporting Therapy De-Escalation
In one recent study, to be discussed during the Dexcom
symposium, 100% of the participating Dexcom CGM users with Type 2
diabetes made dietary changes after starting to use Dexcom CGM5,
with 91% feeling empowered to manage their condition5.
Additionally, 27% reported improved medication adherence after six
months5, underscoring Dexcom CGM's potential to optimise Type 2
diabetes management.
"Studies consistently demonstrate the profound impact Dexcom CGM
has on managing Type 2 diabetes," said Alex Moussa, SVP and GM,
Dexcom EMEA & LATAM. "Across Europe, we're also seeing
long-term cost savings for healthcare systems. As pioneers in
real-time CGM, we're excited about how innovations like Dexcom ONE+
can further benefit healthcare systems and enhance patient
lives."
Recent data from the Danish Steno2Tech trial revealed that twice
as many Dexcom CGM users, compared to those using traditional blood
glucose monitoring, met their HbA1c targets6. For insulin-treated
Type 2 patients with poor glycaemic control, adding CGM
significantly improved outcomes without increasing healthcare
provider hours6. This better glycaemic control is linked to
improved long-term health, fewer complications7, and potential for
therapy de-escalation, particularly in older populations8.
Dexcom’s symposium ‘Thinking together: learnings from 3-real
life cases to improve diabetes management and transform your
clinical practice with CGM’, will take place on Monday 9th
September, 1300 – 1430 CEST, Mumbai Hall, at the EASD
2024Conference in Madrid, Spain. For more information please visit
our microsite.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit https://www.dexcom.com/about.
*Results obtained with Dexcom G6 CGM with Tandem t:slim X2
1 Dexcom data on file 2024. 2 2023 survey amongst HCPs in 8
markets globally, N=291. 3 Brown SA, et al. N Engl J Med
2019;381(18):1707-17. 4 Battelino T, et al. Diabetes Care.
2019;42(8):1593-1603. 5 Clark, et al. Diabetes Technology and
Therapeutics. 2024;doi:10.1089/dia.2023.0612 6 Lind, M et al.
Diabetes Care. 2024;10.2337/dc23-2194. 7 DCCT trial: Diabetes
Control and Complications Trial (DCCT). Diabetes Care. 1987
Jan-Feb;10(1):1-19. 8 Ajjan RA, et al. Nature Reviews Endo.
2024;20:426-440.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904210792/en/
Media Contact: Gemma McDonald +44 (0) 7552 368398
gemma.mcdonald@dexcom.com
Investor Relations Contact: Sean Christensen 858-203-6657
sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
DexCom (NASDAQ:DXCM)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024